<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.2 20060430//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><front><journal-meta><journal-id journal-id-type="nlm-ta">Mediators Inflamm</journal-id><journal-id journal-id-type="publisher-id">MI</journal-id><journal-title>Mediators of Inflammation</journal-title><issn pub-type="ppub">0962-9351</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1155/MI/2006/12587</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Communication</subject></subj-group></article-categories><title-group><article-title>ApoE Polymorphism Is Associated With C-Reactive Protein in Low-HDL Family Members and in Normolipidemic Subjects</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kahri</surname><given-names>Juhani</given-names></name><xref rid="a1" ref-type="aff"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Soro-Paavonen</surname><given-names>Aino</given-names></name><xref rid="a1" ref-type="aff"><sup>1, 2</sup></xref><xref rid="a2" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Ehnholm</surname><given-names>Christian</given-names></name><xref rid="a3" ref-type="aff"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Taskinen</surname><given-names>Marja-Riitta</given-names></name><xref rid="a1" ref-type="aff"><sup>1</sup></xref></contrib></contrib-group><aff id="a1"><sup>1</sup>Division of Cardiology, Department of Internal Medicine, Helsinki University Central Hospital, Haartmaninkatu 4, PO Box 340, 00029 HUS, Finland</aff><aff id="a2"><sup>2</sup>Baker Medical Research Institute, Melbourne, Victoria, Australia</aff><aff id="a3"><sup>3</sup>Department of Molecular Medicine, Biomedicum, National Public Health Institute, 00251 Helsinki, Finland</aff><author-notes><corresp id="cor1">*Juhani Kahri: <email>Juhani.Kahri@hus.fi</email></corresp></author-notes><pub-date pub-type="ppub"><year>2006</year></pub-date><pub-date pub-type="epub"><day>27</day><month>4</month><year>2006</year></pub-date><volume>2006</volume><issue>3</issue><elocation-id>12587</elocation-id><history><date date-type="received"><day>30</day><month>12</month><year>2005</year></date><date date-type="rev-recd"><day>15</day><month>3</month><year>2006</year></date><date date-type="accepted"><day>20</day><month>3</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 Juhani Kahri et al.</copyright-statement><copyright-year>2006</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>The study was aimed to compare inflammatory parameters between carriers of apoE4 isoforms (apoE4/3, apoE4/2, and apoE4/4 phenotypes) and those of carrying apoE3 isoform without apoE4 isoform (apoE3/3 phenotypes and apoE2/3 phenotypes). The concentrations of serum hsCRP, sVCAM-1, sICAM-1, and sE-selectin were measured in 211 subjects from Finnish low-HDL families and in 157 normolipidemic subjects. The subjects with apoE4 isoform had lower concentrations of serum hsCRP both in low-HDL family members (<italic>p</italic> &#x0003c; 0.05) and in normolipidemic subjects (<italic>p</italic> &#x0003c; 0.01). The differences in serum CRP values remained significant after adjustment for age, BMI, smoking status, hypertension, gender, lipoprotein variables, and family number. We conclude that apoE phenotype has a strong influence on serum CRP values.</p></abstract></article-meta></front><body><sec sec-type="introduction"><title>INTRODUCTION</title><p>A substantial body of evidence indicates, that low-grade inflammation in the vascular endothelium promotes atherogenesis [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>]. This is indirectly evidenced by the fact that several inflammatory markers are linked to an increased risk of atherosclerosis. High-sensitive CRP (hsCRP) has been reported to associate with an increased risk of myocardial infarction, stroke, sudden death from cardiac causes, and peripheral arterial disease [<xref ref-type="bibr" rid="B3">3</xref>]. In addition, hsCRP has been shown to predict the first cardiovascular event better than low-density lipoprotein cholesterol (LDL-C) [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Recruitment of inflammatory cells from the circulation and their transendothelial migration is one of the earliest phases of atherogenesis [<xref ref-type="bibr" rid="B3">3</xref>]. Vascular endothelium expresses cellular adhesion molecules (CAMs) in response to several inflammatory stimuli [<xref ref-type="bibr" rid="B4">4</xref>]. The evidence for the role of CAMs in the pathogenesis of atherosclerosis has emerged from experimental studies which have demonstrated the focal expression of adhesion molecules in atherosclerotic plaques [<xref ref-type="bibr" rid="B4">4</xref>&#x02013;<xref ref-type="bibr" rid="B6">6</xref>]. </p><p>Different CAMs have various functions in the vasculature. Selectins and their ligands are involved in the first steps in leukocyte adhesion at sites of endothelial injury as they mediate the rolling and tethering of leukocytes in the vascular wall [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>]. Intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) induce firm adhesion of inflammatory cells to the vascular surface [<xref ref-type="bibr" rid="B3">3</xref>]. Overall, both soluble ICAM-1 (sICAM-1) and soluble VCAM-1 (sVCAM-1) have been linked to increase risk of atherosclerosis [<xref ref-type="bibr" rid="B7">7</xref>&#x02013;<xref ref-type="bibr" rid="B9">9</xref>].</p><p>Apolipoprotein E (apoE) is secreted from hepatocytes and macrophages. ApoE is transported in lipoproteins, and it regulates the hepatic uptake of remnant lipoproteins and facilitates cholesterol efflux from foam cells [<xref ref-type="bibr" rid="B10">10</xref>]. In addition, apoE has a central role in inflammation and in mediating the central nervous system response to injury [<xref ref-type="bibr" rid="B11">11</xref>&#x02013;<xref ref-type="bibr" rid="B13">13</xref>]. There are three common ApoE isoforms, designated E2, E3, and E4, which are encoded for by distinct alleles on human chromosome 19. ApoE isoforms are distributed in six different phenotypes E2/2, E2/3, E3/3, E4/2, E4/3, and E4/4 [<xref ref-type="bibr" rid="B10">10</xref>]. The presence of E4 isoform is associated with coronary heart disease [<xref ref-type="bibr" rid="B14">14</xref>] and with the early onset of Alzheimer's disease [<xref ref-type="bibr" rid="B15">15</xref>].</p><p>So far, there are sparse data on apoE polymorphism in relation to the parameters of inflammation. M&#x000e4;ntt&#x000e4;ri et al [<xref ref-type="bibr" rid="B16">16</xref>] showed that dyslipidemic men with E4/4, E4/3, and E4/2 phenotypes exhibit lower CRP values than men carrying other apoE phenotypes. In a recent report by M&#x000e4;rz et al [<xref ref-type="bibr" rid="B17">17</xref>], carriers of apoE2 allele and apoE3/3 homozygotes had significantly higher CRP than individuals with the genotypes apoE3/4 and apoE4/4. In dyslipidemic men and women, C-reactive protein has been reported to be lower in subjects with one or two copies of E4 allele than in those with zero E4 allele [<xref ref-type="bibr" rid="B18">18</xref>]. Paradoxically, E4 allele has been associated with an enhanced inflammatory reaction after cardiopulmonary bypass [<xref ref-type="bibr" rid="B19">19</xref>]. In line, transgenic mice expressing the E4 allele had greater systemic and brain elevations of proinflammatory cytokines than E3 carriers [<xref ref-type="bibr" rid="B20">20</xref>].</p><p>We hypothesize that the apoE phenotype, as a critical component in inflammatory processes, may influence the levels of inflammation markers. HDL has been demonstrated to exhibit antiinflammatory properties by inhibiting cytokine induced expression of adhesion molecules [<xref ref-type="bibr" rid="B21">21</xref>&#x02013;<xref ref-type="bibr" rid="B23">23</xref>]. In contrast, acute inflammation process may decrease HDL concentration and thus compromise its antiatherogenic function [<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>]. Interestingly, recycling of apoE is closely linked to HDL metabolism [<xref ref-type="bibr" rid="B26">26</xref>]. Therefore we studied the effects of apoE phenotype on the levels of CRP and sCAMs on a sample of Finnish low-HDL families and in normolipidemic subjects.</p></sec><sec sec-type="subjects and methods"><title>SUBJECTS AND METHODS</title><p>The study subjects were recruited according to the study protocol as reported previously [<xref ref-type="bibr" rid="B27">27</xref>]. To identify the low-HDL families, first degree relatives of the probands were examined. The family members were coded as affected if their HDL-C levels were below the 10th percentile cut-off levels. If at least two affected subjects were identified in the family, all available second-degree relatives and spouses were contacted and included in the study. The blood samples for the lipid and lipoprotein analysis were taken at the same visit as the inflammation parameters and therefore the lipid and lipoprotein values in this study represent the values of that visit, and not those of the screening visit. Altogether 211 low-HDL family members and 157 normolipidemic subjects had measures of their apoE phenotype, hsCRP, and sVCAM-1 concentrations. Seventeen low-HDL subjects had history of CHD. The normolipidemic group comprised healthy volunteers and normolipidemic spouses from the low-HDL families. They were required to have no signs of CHD or diabetes, and no lipid lowering medication. The smoking status of the patients was categorized into current smokers and nonsmokers (including exsmokers). Hypertension was defined as self-reported use of antihypertensive drugs, systolic blood pressure &#x02265; 140 mmHg, or diastolic blood pressure &#x02265; 90 mmHg. Estrogen use was defined as any means of estrogen administration (oral contraceptives, or oral or transdermal postmenopausal hormone replacement therapy). Venous blood samples were collected after overnight fasting. Serum was separated and used for the biochemical measurements. Lipid and lipoprotein measurements were done from serum as described previously [<xref ref-type="bibr" rid="B27">27</xref>]. Serum levels of sICAM-1, sVCAM-1, and sE-selectin were measured by using commercially available monoclonal antibody-based ELISAs (R &#x00026; D Systems, Minneapolis, MN, USA). Serum highly sensitive CRP (hsCRP) was determined by a commercial kit from Medix Biochemica, Kauniainen, Finland. Subjects with CRP levels over 10 mg/l were excluded. ApoE phenotype was determined by the method of Havekes et al [<xref ref-type="bibr" rid="B28">28</xref>]. Statistical comparisons of clinical and biochemical parameters were performed with SPSS 11.0 for Windows (SPSS Inc., Chigaco, IL, USA). Data are expressed as mean &#x000b1; standard error of mean (SEM). Continuous variables were compared between two groups by Student <italic>t</italic> test. Variables with nonnormal distribution were <mml:math id="M1"><mml:mrow><mml:msub><mml:mrow><mml:mi>log</mml:mi><mml:mo>&#x02061;</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math>-transformed before comparison. <italic>P</italic> &#x0003c; .05 was considered to be significant (two-tailed). The frequency distribution between the groups was compared with the Chi-square test. The correlation coefficients between the biochemical and clinical characteristics were examined by Pearson's correlation for continuous variables. Multiple regression analysis was performed to determine the relative contribution of different variables to hsCRP and sVCAM-1 values. In the low-HDL group, the subjects came from 47 different families. Ten families had only one subject, and five families had 11&#x02013;16 subjects. Because the subjects in the present cohort were not independent, we used the family number (which indicates belonging to a certain family) as a random variable. Family-number-adjusted residuals of log CRP and log VCAM were used in the multiple regression model for low-HDL family members. Since control subjects were not related, the family-number adjustment was performed only in the low-HDL group.</p></sec><sec sec-type="results"><title>RESULTS</title><p>The effects of apoE phenotype was studied by dividing subjects into two subgroups (apoE groups): into the E3 group, which included E3/2 and E3/3 phenotypes, and into the E4 group which included E4/2, E4/3, and E4/4 phenotypes. Clinical and biochemical characteristics of the study subjects are presented in <xref ref-type="table" rid="T1">Table 1</xref>.</p><p><xref ref-type="table" rid="T2">Table 2</xref> shows that serum hsCRP values were significantly lower in the E4 than in the E3 subgroup both in the low-HDL group (<italic>P</italic> &#x0003c; .01) and in the normolipidemic group (<italic>P</italic> &#x0003c; .05) after adjustment for age, BMI, serum apoA-I, apoA-II, apoB, HDL-C, LDL-C, triglycerides, smoking status, hypertension, and gender in normolipidemic subjects, and after additional adjustment for family number in the low-HDL group. The concentration of serum sVCAM-1 was significantly lower in the E4 group than in the E3 group in low-HDL subjects (<italic>P</italic> &#x0003c; .01) but the significance disappeared after adjustment for family number (<xref ref-type="table" rid="T2">Table 2</xref>). Multiple regression analysis revealed that apoE phenotype was a significant predictor of serum hsCRP values both in low-HDL and normolipidemic subjects (<italic>P</italic> = .023 and <italic>P</italic> = .011, resp) (<xref ref-type="table" rid="T3">Table 3</xref>). Estrogen used was also a strong predictor of serum hsCRP concentration in low-HDL subjects (<italic>P</italic> = .026) as well as in normolpidemic subjects (<italic>P</italic> = .036) (<xref ref-type="table" rid="T3">Table 3</xref>)</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The major finding of the present study is that subjects presenting the apoE4 allele have decreased levels of serum hsCRP. This is an interesting observation, since ApoE plays a central role in inflammation and atherosclerosis. ApoE knockout mice are especially prone to atherosclerosis [<xref ref-type="bibr" rid="B10">10</xref>] and to die from lipopolysaccharide (LPS)-induced sepsis [<xref ref-type="bibr" rid="B11">11</xref>]. ApoE participates in cholesterol efflux, and has been observed to be recycled from triglyceride-rich lipoproteins into HDL-particles [<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B26">26</xref>]. In mice, exogenous apoE injection has been demonstrated to decrease the LPS-induced production of proinflammatory cytokines, probable by decreasing the release of cytokines from macrophages, which was accompanied by reduced mortality [<xref ref-type="bibr" rid="B11">11</xref>]. CRP and apoE concentrations are inversely related in obese patients [<xref ref-type="bibr" rid="B12">12</xref>]. In addition, human CRP transgene expression has been shown to cause accelerated atherosclerosis in apolipoprotein E-deficient mice [<xref ref-type="bibr" rid="B13">13</xref>]. Thus, according to these studies, the role of apoE in inflammation and atherosclerosis may be protective.</p><p>Despite the importance of apoE in the inflammatory process, only few studies have linked apoE polymorphisms to inflammatory parameters. In the central nervous system, apoE4 has been reported to be less effective than apoE3 or apoE2 at suppressing the activation of microglia in cell culture models of brain inflammation [<xref ref-type="bibr" rid="B29">29</xref>]. Transgenic mice expressing the apoE4 allele have significantly greater systemic and brain elevations of proinflammatory cytokines TNF-alpha and IL-6 as compared with their apoE3 counterparts [<xref ref-type="bibr" rid="B20">20</xref>]. In the present study, the hsCRP concentration was significantly lower in subjects exhibiting apoE4 allele than in those exhibiting other alleles. Likewise, M&#x000e4;ntt&#x000e4;ri and associates demonstrated, in a population of 179 dyslipidemic Finnish men, that subjects with apoE4/3 phenotype had lower mean CRP concentration than those with apoE3/3 phenotype [<xref ref-type="bibr" rid="B16">16</xref>]. In Japanese Americans, CRP values have been reported to be significantly higher in apoE2 carriers than in apoE3 or apoE4 carriers, and similar between apoE3 and apoE4 carriers [<xref ref-type="bibr" rid="B30">30</xref>]. In line with the Japanese data, German patients with or without coronary heart disease also showed higher CRP values in apoE2 carriers than in apoE3/4 heterozygotes or in apoE4/4 homozygotes [<xref ref-type="bibr" rid="B17">17</xref>]. However, CRP was also significantly higher in apoE3/3 homozygotes than in apoE3/4 heterozygotes or in apoE4/4 homozygotes [<xref ref-type="bibr" rid="B17">17</xref>]. Similarly, in the Cardiovascular Health Study [<xref ref-type="bibr" rid="B31">31</xref>], CRP values were lower in apoE4 positive than in apoE4 negative individuals independently of the amount of used alcohol. Thus, the present data extend these previous observations to a cohort of low-HDL family members as well as to normolipidemic subjects.</p><p>The mechanisms behind low serum CRP values in apoE4 carriers in this study, and in previous works [<xref ref-type="bibr" rid="B16">16</xref>&#x02013;<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B31">31</xref>] are unclear. Since apoE phenotype remained as a predictor of hsCRP in multiple regression model, the difference between apoE4 and apoE3 groups can not be explained by confounding factors, such as estrogen use. One explanation, originally suggested by M&#x000e4;rz and associates [<xref ref-type="bibr" rid="B17">17</xref>], could be that the metabolism of CRP is related to mevalonate pathway. In carriers of apoE4, the mevalonate pathway may be down-regulated resulting in decreased CRP [<xref ref-type="bibr" rid="B17">17</xref>].</p><p>The observed low serum CRP values in apoE4 carriers in the present study, and reportedly low CRP values in apoE4 carriers in previous works [<xref ref-type="bibr" rid="B16">16</xref>&#x02013;<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B31">31</xref>], are perplexing findings since apoE4 allele is associated to an increased risk of atherosclerosis [<xref ref-type="bibr" rid="B14">14</xref>]. However, in the present study, the low-HDL family members within the E4 group had an atherogenic lipid profile: they had higher concentrations of apoB, a trend for higher serum triglycerides, and lower concentration of HDL-C as compared with the E3 group. Thus, the changes in lipoproteins rather than changes in inflammatory parameters may explain the atherogenity of apoE4 allele.</p><p>We conclude that apoE phenotype has a strong influence on C-reactive protein. ApoE may be a double-faced protein having different actions in lipid metabolism and inflammation.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>We thank all the study subjects for participating in this study. Virve Naatti, Helin&#x000e4; Perttunen-Nio, and Hannele Hilden are thanked for their excellent technical assistance. This work was supported by grants from the Finnish Cardiovascular Research Foundation, Special State Grants for health science research, The Finnish Medical Society Duodecim, The Sigrid Juselius Foundation, The International HDL Research Awards, The Paulo Foundation, Aarne Koskelo Foundation, Maud Kuistila Foundation, and The Biomedicum Helsinki Foundation.</p></ack><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>R</given-names></name></person-group><article-title>Atherosclerosis&#x02014;an inflammatory disease</article-title><source><italic>New England Journal of Medicine</italic></source><year>1999</year><volume>340</volume><issue>2</issue><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">9887164</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Maseri</surname><given-names>A</given-names></name></person-group><article-title>Inflammation and atherosclerosis</article-title><source><italic>Circulation</italic></source><year>2002</year><volume>105</volume><issue>9</issue><fpage>1135</fpage><lpage>1143</lpage><pub-id pub-id-type="pmid">11877368</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Rose</surname><given-names>L</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Cook</surname><given-names>NR</given-names></name></person-group><article-title>Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events</article-title><source><italic>New England Journal of Medicine</italic></source><year>2002</year><volume>347</volume><issue>20</issue><fpage>1557</fpage><lpage>1565</lpage><pub-id pub-id-type="pmid">12432042</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blankenberg</surname><given-names>S</given-names></name><name><surname>Barbaux</surname><given-names>S</given-names></name><name><surname>Tiret</surname><given-names>L</given-names></name></person-group><article-title>Adhesion molecules and atherosclerosis</article-title><source><italic>Atherosclerosis</italic></source><year>2003</year><volume>170</volume><issue>2</issue><fpage>191</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">14612198</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>MJ</given-names></name><name><surname>Gordon</surname><given-names>JL</given-names></name><name><surname>Gearing</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis</article-title><source><italic>Journal of Pathology</italic></source><year>1993</year><volume>171</volume><issue>3</issue><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">7506307</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>KD</given-names></name><name><surname>McDonald</surname><given-names>TO</given-names></name><name><surname>Chait</surname><given-names>A</given-names></name><name><surname>Allen</surname><given-names>MD</given-names></name><name><surname>Alpers</surname><given-names>CE</given-names></name></person-group><article-title>Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content</article-title><source><italic>Circulation</italic></source><year>1996</year><volume>93</volume><issue>4</issue><fpage>672</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">8640995</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>SJ</given-names></name><name><surname>Ballantyne</surname><given-names>CM</given-names></name><name><surname>Sharrett</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. The atherosclerosis risk in communities (ARIC) study</article-title><source><italic>Circulation</italic></source><year>1997</year><volume>96</volume><issue>12</issue><fpage>4219</fpage><lpage>4225</lpage><pub-id pub-id-type="pmid">9416885</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name><name><surname>Roitman-Johnson</surname><given-names>B</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Allen</surname><given-names>J</given-names></name></person-group><article-title>Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men</article-title><source><italic>Lancet</italic></source><year>1998</year><volume>351</volume><issue>9096</issue><fpage>88</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">9439492</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rohde</surname><given-names>LE</given-names></name><name><surname>Lee</surname><given-names>RT</given-names></name><name><surname>Rivero</surname><given-names>J</given-names></name><etal/></person-group><article-title>Circulating cell adhesion molecules are correlated with ultrasound-based assesment of carotid atherosclerosis</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>1998</year><volume>18</volume><issue>11</issue><fpage>1765</fpage><lpage>1770</lpage></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davignon</surname><given-names>J</given-names></name><name><surname>Cohn</surname><given-names>JS</given-names></name><name><surname>Mabile</surname><given-names>L</given-names></name><name><surname>Bernier</surname><given-names>L</given-names></name></person-group><article-title>Apolipoprotein E and atherosclerosis: insight from animal and human studies</article-title><source><italic>Clinica Chimica Acta</italic></source><year>1999</year><volume>286</volume><issue>1-2</issue><fpage>115</fpage><lpage>143</lpage></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Oosten</surname><given-names>M</given-names></name><name><surname>Rensen</surname><given-names>PCN</given-names></name><name><surname>Van Amersfoort</surname><given-names>ES</given-names></name><etal/></person-group><article-title>Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat Gram-negative sepsis</article-title><source><italic>Journal of Biological Chemistry</italic></source><year>2001</year><volume>276</volume><issue>12</issue><fpage>8820</fpage><lpage>8824</lpage><pub-id pub-id-type="pmid">11136731</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bach-Ngohou</surname><given-names>K</given-names></name><name><surname>Nazih</surname><given-names>H</given-names></name><name><surname>Nazih-Sanderson</surname><given-names>F</given-names></name><etal/></person-group><article-title>Negative and independent influence of apolipoprotein E on C-reactive protein (CRP) concentration in obese adults. Potential antiinflammatory role of apoE in vivo</article-title><source><italic>International Journal of Obesity</italic></source><year>2001</year><volume>25</volume><issue>12</issue><fpage>1752</fpage><lpage>1758</lpage><pub-id pub-id-type="pmid">11781754</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>A</given-names></name><name><surname>Ko</surname><given-names>KWS</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice</article-title><source><italic>Circulation</italic></source><year>2004</year><volume>109</volume><issue>5</issue><fpage>647</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">14744975</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group><article-title>Meta-analysis: apolipoprotein E genotypes and risk of coronary heart disease</article-title><source><italic>Annals of Internal Medicine</italic></source><year>2004</year><volume>141</volume><issue>2</issue><fpage>137</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">15262670</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strittmatter</surname><given-names>WJ</given-names></name><name><surname>Roses</surname><given-names>AD</given-names></name></person-group><article-title>Apolipoprotein E and Alzheimer's disease</article-title><source><italic>Annual Review of Neuroscience</italic></source><year>1996</year><volume>19</volume><fpage>53</fpage><lpage>77</lpage></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e4;ntt&#x000e4;ri</surname><given-names>M</given-names></name><name><surname>Manninen</surname><given-names>V</given-names></name><name><surname>Palosuo</surname><given-names>T</given-names></name><name><surname>Ehnholm</surname><given-names>C</given-names></name></person-group><article-title>Apolipoprotein E polymorphism and C-reactive protein in dyslipidemic middle aged men</article-title><source><italic>Atherosclerosis</italic></source><year>2001</year><volume>156</volume><issue>1</issue><fpage>237</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">11417521</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e4;rz</surname><given-names>W</given-names></name><name><surname>Sxharnagl</surname><given-names>H</given-names></name><name><surname>Hoffman</surname><given-names>MM</given-names></name><name><surname>Boehm</surname><given-names>BO</given-names></name><name><surname>Winkelmann</surname><given-names>BR</given-names></name></person-group><article-title>The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study)</article-title><source><italic>European Heart Journal</italic></source><year>2004</year><volume>25</volume><issue>23</issue><fpage>2109</fpage><lpage>2119</lpage><pub-id pub-id-type="pmid">15571826</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Judson</surname><given-names>R</given-names></name><name><surname>Brain</surname><given-names>C</given-names></name><name><surname>Dain</surname><given-names>B</given-names></name><name><surname>Windemuth</surname><given-names>A</given-names></name><name><surname>Ruano</surname><given-names>G</given-names></name><name><surname>Red</surname><given-names>C</given-names></name></person-group><article-title>New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals</article-title><source><italic>Atherosclerosis</italic></source><year>2004</year><volume>177</volume><issue>2</issue><fpage>345</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">15530909</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grocott</surname><given-names>HP</given-names></name><name><surname>Newman</surname><given-names>MF</given-names></name><name><surname>El-Moalem</surname><given-names>H</given-names></name><name><surname>Bainbridge</surname><given-names>D</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Laskowitz</surname><given-names>DT</given-names></name></person-group><article-title>Apolipoprotein E genotype differentially influences the proinflammatory and anti-inflammatory response to cardiopulmonary bypass</article-title><source><italic>Journal of Thoracic and Cardiovascular Surgery</italic></source><year>2001</year><volume>122</volume><issue>3</issue><fpage>622</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">11547323</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>JR</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>ApoE genotype and an apoEmimetic peptide modify the systemic and central nervous system inflammatory response</article-title><source><italic>Journal of Biological Chemistry</italic></source><year>2003</year><volume>273</volume><issue>49</issue><fpage>48529</fpage><lpage>48533</lpage><pub-id pub-id-type="pmid">14507923</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cockerill</surname><given-names>GW</given-names></name><name><surname>Rye</surname><given-names>KA</given-names></name><name><surname>Gamble</surname><given-names>JR</given-names></name><name><surname>Vadas</surname><given-names>MA</given-names></name><name><surname>Barter</surname><given-names>PJ</given-names></name></person-group><article-title>High-density lipoprotein inhibit cytokine-induced expression of endothelial cell adhesion molecule</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>1995</year><volume>15</volume><issue>11</issue><fpage>1987</fpage><lpage>1994</lpage></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cockerill</surname><given-names>GW</given-names></name><name><surname>Huehns</surname><given-names>TY</given-names></name><name><surname>Weerasinghe</surname><given-names>A</given-names></name><etal/></person-group><article-title>Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation</article-title><source><italic>Circulation</italic></source><year>2001</year><volume>103</volume><issue>1</issue><fpage>108</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">11136694</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calabresi</surname><given-names>L</given-names></name><name><surname>Franceschini</surname><given-names>G</given-names></name><name><surname>Sirtori</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Inhibition of VCAM-1 expression in endothelial cells by reconstituted high-density lipoproteins</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>1997</year><volume>1238</volume><issue>1</issue><fpage>61</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">9299452</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tietge</surname><given-names>UJF</given-names></name><name><surname>Maugeais</surname><given-names>C</given-names></name><name><surname>Cain</surname><given-names>W</given-names></name><etal/></person-group><article-title>Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I</article-title><source><italic>Journal of Biological Chemistry</italic></source><year>1999</year><volume>275</volume><issue>14</issue><fpage>10077</fpage><lpage>10084</lpage><pub-id pub-id-type="pmid">10744687</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tietge</surname><given-names>UJF</given-names></name><name><surname>Maugeais</surname><given-names>C</given-names></name><name><surname>Lund-Katz</surname><given-names>S</given-names></name><name><surname>Grass</surname><given-names>D</given-names></name><name><surname>deBeer</surname><given-names>FC</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name></person-group><article-title>Human secretory phospholipase A2 (sPLA2) mediates decreased plasma levels of HDL-cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2002</year><volume>22</volume><issue>7</issue><fpage>1213</fpage><lpage>1218</lpage></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heeren</surname><given-names>J</given-names></name><name><surname>Grewal</surname><given-names>T</given-names></name><name><surname>Laatsch</surname><given-names>A</given-names></name><etal/></person-group><article-title>Recycling of apoprotein E is associated with cholesterol efflux and high density lipoprotein internalization</article-title><source><italic>Journal of Biological Chemistry</italic></source><year>2003</year><volume>278</volume><issue>16</issue><fpage>14370</fpage><lpage>14378</lpage><pub-id pub-id-type="pmid">12584196</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alagona</surname><given-names>C</given-names></name><name><surname>Soro-Paavonen</surname><given-names>A</given-names></name><name><surname>Ylitalo</surname><given-names>K</given-names></name><name><surname>Salonen</surname><given-names>R</given-names></name><name><surname>Salonen</surname><given-names>JT</given-names></name><name><surname>Taskinen</surname><given-names>M-R</given-names></name></person-group><article-title>A low high density lipoprotein (HDL) level is associated with carotid artery intima-media thickness in asymptomatic members of low HDL families</article-title><source><italic>Atherosclerosis</italic></source><year>2002</year><volume>165</volume><issue>2</issue><fpage>309</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">12417282</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Havekes</surname><given-names>LM</given-names></name><name><surname>de Knijff</surname><given-names>P</given-names></name><name><surname>Beisiegel</surname><given-names>U</given-names></name><name><surname>Havinga</surname><given-names>J</given-names></name><name><surname>Smit</surname><given-names>M</given-names></name><name><surname>Klasen</surname><given-names>E</given-names></name></person-group><article-title>A rapid micromethod for apolipoprotein E phenotyping directly in serum</article-title><source><italic>Journal of Lipid Research</italic></source><year>1987</year><volume>28</volume><issue>4</issue><fpage>455</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">3585179</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barger</surname><given-names>SW</given-names></name><name><surname>Harmon</surname><given-names>AD</given-names></name></person-group><article-title>Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E</article-title><source><italic>Nature</italic></source><year>1997</year><volume>388</volume><issue>6645</issue><fpage>878</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">9278049</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>MA</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Humphries</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Heritability of Creactive protein and association with apolipoprotein E genotypes in Japanese Americans</article-title><source><italic>Annals of Human Genetics</italic></source><year>2004</year><volume>68</volume><issue>3</issue><fpage>179</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">15180698</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mukamal</surname><given-names>KJ</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><name><surname>Mittleman</surname><given-names>MA</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Siscovick</surname><given-names>DS</given-names></name></person-group><article-title>Alcohol consumption and inflammatory markers in older adults: the Cardiovascular Health Study</article-title><source><italic>Atherosclerosis</italic></source><year>2004</year><volume>173</volume><issue>1</issue><fpage>79</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">15177126</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>The clinical characteristics and lipid values of the study subjects.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="1" colspan="1"/><td colspan="2" align="center" rowspan="1">Low-HDL subjects <italic>n</italic> = 211</td><td colspan="2" align="center" rowspan="1">Normolipidemic subjects <italic>n</italic> = 157</td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">E3 group</td><td align="center" rowspan="1" colspan="1">E4 group</td><td align="center" rowspan="1" colspan="1">E3 group</td><td align="center" rowspan="1" colspan="1">E4 group</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>N</italic> = 140</td><td align="center" rowspan="1" colspan="1"><italic>N</italic> = 71</td><td align="center" rowspan="1" colspan="1"><italic>N</italic> = 101</td><td align="center" rowspan="1" colspan="1"><italic>N</italic> = 56</td></tr><tr><td rowspan="1" colspan="1">AGE (y)</td><td align="center" rowspan="1" colspan="1">41.5 &#x000b1; 1.2</td><td align="center" rowspan="1" colspan="1">41.5 &#x000b1; 1.8</td><td align="center" rowspan="1" colspan="1">51.8 &#x000b1; 1.1</td><td align="center" rowspan="1" colspan="1">49.3 &#x000b1; 1.8</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m2)</td><td rowspan="1" colspan="1">25.6 &#x000b1; 0.3</td><td align="center" rowspan="1" colspan="1">25.6 &#x000b1; 0.5</td><td align="center" rowspan="1" colspan="1">24.9 &#x000b1; 0.4</td><td align="center" rowspan="1" colspan="1">24.3 &#x000b1; 0.4</td></tr><tr><td rowspan="1" colspan="1">Gender (male/female)</td><td align="center" rowspan="1" colspan="1">68/72</td><td align="center" rowspan="1" colspan="1">41/30</td><td align="center" rowspan="1" colspan="1">45/56</td><td align="center" rowspan="1" colspan="1">25/31</td></tr><tr><td rowspan="1" colspan="1">Smokers (%)</td><td align="center" rowspan="1" colspan="1">17.1%</td><td align="center" rowspan="1" colspan="1">31.0%<xref ref-type="table-fn" rid="TF1">*</xref></td><td align="center" rowspan="1" colspan="1">18.8%</td><td align="center" rowspan="1" colspan="1">16.1%</td></tr><tr><td rowspan="1" colspan="1">Hypertension(%)</td><td align="center" rowspan="1" colspan="1">27.1%</td><td align="center" rowspan="1" colspan="1">22.5%</td><td align="center" rowspan="1" colspan="1">27.7%</td><td align="center" rowspan="1" colspan="1">17.9%</td></tr><tr><td rowspan="1" colspan="1">Estrogen use(%)</td><td align="center" rowspan="1" colspan="1">17.1%</td><td align="center" rowspan="1" colspan="1">18.3%</td><td align="center" rowspan="1" colspan="1">15.8%</td><td align="center" rowspan="1" colspan="1">19.6%</td></tr><tr><td rowspan="1" colspan="1">Cholesterol (mmol/l)</td><td align="center" rowspan="1" colspan="1">5.05 &#x000b1; 0.07</td><td align="center" rowspan="1" colspan="1">5.27 &#x000b1; 0.13</td><td align="center" rowspan="1" colspan="1">5.05 &#x000b1; 0.08</td><td align="center" rowspan="1" colspan="1">5.13 &#x000b1; 0.11</td></tr><tr><td rowspan="1" colspan="1">Triglycerides (mmol/l)</td><td align="center" rowspan="1" colspan="1">1.32 &#x000b1; 0.06</td><td align="center" rowspan="1" colspan="1">1.53 &#x000b1; 0.09</td><td align="center" rowspan="1" colspan="1">1.05 &#x000b1; 0.08</td><td align="center" rowspan="1" colspan="1">0.95 &#x000b1; 0.04</td></tr><tr><td rowspan="1" colspan="1">HDL-cholesterol (mmol/l)</td><td align="center" rowspan="1" colspan="1">1.30 &#x000b1; 0.04</td><td align="center" rowspan="1" colspan="1">1.14 &#x000b1; 0.04<xref ref-type="table-fn" rid="TF1">*</xref></td><td align="center" rowspan="1" colspan="1">1.51 &#x000b1; 0.04</td><td align="center" rowspan="1" colspan="1">1.51 &#x000b1; 0.05</td></tr><tr><td rowspan="1" colspan="1">LDL-cholesterol (mmol/l)</td><td align="center" rowspan="1" colspan="1">3.15 &#x000b1; 0.08</td><td align="center" rowspan="1" colspan="1">3.43 &#x000b1; 0.12</td><td align="center" rowspan="1" colspan="1">3.07 &#x000b1; 0.07</td><td align="center" rowspan="1" colspan="1">3.19 &#x000b1; 0.10</td></tr><tr><td rowspan="1" colspan="1">ApoA-I (mg/dl)</td><td align="center" rowspan="1" colspan="1">136 &#x000b1; 2</td><td align="center" rowspan="1" colspan="1">129 &#x000b1; 2</td><td align="center" rowspan="1" colspan="1">147 &#x000b1; 3</td><td align="center" rowspan="1" colspan="1">145 &#x000b1; 3</td></tr><tr><td rowspan="1" colspan="1">ApoA-II (mg/dl)</td><td align="center" rowspan="1" colspan="1">36 &#x000b1; 1</td><td align="center" rowspan="1" colspan="1">36 &#x000b1; 1</td><td align="center" rowspan="1" colspan="1">37 &#x000b1; 1</td><td align="center" rowspan="1" colspan="1">37 &#x000b1; 1</td></tr><tr><td rowspan="1" colspan="1">ApoB (mg/dl)</td><td align="center" rowspan="1" colspan="1">98 &#x000b1; 2</td><td align="center" rowspan="1" colspan="1">106 &#x000b1; 3<xref ref-type="table-fn" rid="TF1">&#x02021;</xref></td><td align="center" rowspan="1" colspan="1">91 &#x000b1; 2</td><td align="center" rowspan="1" colspan="1">91 &#x000b1; 2</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as means &#x000b1; SEMs.</p></fn><fn id="TF1"><p>*<italic>P</italic> &#x0003c; .05, <sup>&#x02021;</sup><italic>P</italic> &#x0003c; .06 after adjustment for smoking.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>The concentrations of hsCRP, sVCAM-1, sICAM-1, and sE-SELECTIN in Low-HDL subjects and normolipidemic subjects divided by apoE subgroups.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" rowspan="1" colspan="1"/><td colspan="2" align="center" rowspan="1">Low-HDL subjects <italic>n</italic> = 211</td><td colspan="2" align="center" rowspan="1">Normolipidemic subjects <italic>n</italic> = 157</td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="1" colspan="1"/><td colspan="1" align="center" rowspan="1">E3 group <italic>n</italic> = 140</td><td colspan="1" align="center" rowspan="1">E4 group <italic>n</italic> = 71</td><td colspan="1" align="center" rowspan="1">E3 group <italic>n</italic> = 101</td><td colspan="1" align="center" rowspan="1">E4 group <italic>n</italic> = 56</td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1">CRP (mg/l)</td><td align="center" rowspan="1" colspan="1">1.72 &#x000b1; 0.16</td><td align="center" rowspan="1" colspan="1">1.14 &#x000b1; 0.17<xref ref-type="table-fn" rid="TF2">**</xref></td><td align="center" rowspan="1" colspan="1">1.29 &#x000b1; 0.14</td><td align="center" rowspan="1" colspan="1">0.63 &#x000b1; 0.08<xref ref-type="table-fn" rid="TF2">*</xref></td></tr><tr><td rowspan="1" colspan="1">sVCAM-1 (ng/ml)</td><td align="center" rowspan="1" colspan="1">540 &#x000b1; 11</td><td align="center" rowspan="1" colspan="1">478 &#x000b1; 12</td><td align="center" rowspan="1" colspan="1">496 &#x000b1; 10</td><td align="center" rowspan="1" colspan="1">494 &#x000b1; 13</td></tr><tr><td rowspan="1" colspan="1">sICAM-1 (ng/ml)</td><td align="center" rowspan="1" colspan="1">234 &#x000b1; 5</td><td align="center" rowspan="1" colspan="1">238 &#x000b1; 7</td><td align="center" rowspan="1" colspan="1">223 &#x000b1; 6</td><td align="center" rowspan="1" colspan="1">236 &#x000b1; 5</td></tr><tr><td rowspan="1" colspan="1">sE-selectin (ng/ml)</td><td align="center" rowspan="1" colspan="1">49 &#x000b1; 2</td><td align="center" rowspan="1" colspan="1">50 &#x000b1; 2</td><td align="center" rowspan="1" colspan="1">45 &#x000b1; 2</td><td align="center" rowspan="1" colspan="1">50 &#x000b1; 8</td></tr></tbody></table><table-wrap-foot><fn id="TF2"><p>Data are expressed as means &#x000b1; SEMs. **<italic>P</italic> &#x0003c; .01; *<italic>P</italic> &#x0003c; .05 for the comparison with the E3 group after adjustment for age, gender, BMI, hypertension, smoking status, and lipoprotein variables; and family number in the low-HDL group.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Multiple regression analysis of predictors of CRP values in low-HDL and normolipidemic subjects.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" rowspan="1" colspan="1"/><td colspan="2" align="center" rowspan="1">Low-HDL subjects</td><td colspan="2" align="center" rowspan="1">Normolipidemic subjects</td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1">Variable</td><td align="center" rowspan="1" colspan="1">Standardized &#x003b2;</td><td align="center" rowspan="1" colspan="1"><italic>P</italic></td><td align="center" rowspan="1" colspan="1">Standardized &#x003b2;</td><td align="center" rowspan="1" colspan="1"><italic>P</italic></td></tr><tr><td rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">+0.147</td><td align="center" rowspan="1" colspan="1">.080</td><td align="center" rowspan="1" colspan="1">+0.244</td><td align="center" rowspan="1" colspan="1">.003</td></tr><tr><td rowspan="1" colspan="1">BMI</td><td align="center" rowspan="1" colspan="1">+0.339</td><td align="center" rowspan="1" colspan="1">&#x0003c; .001</td><td align="center" rowspan="1" colspan="1">+0.315</td><td align="center" rowspan="1" colspan="1">&#x0003c; .001</td></tr><tr><td rowspan="1" colspan="1">Smoking status</td><td align="center" rowspan="1" colspan="1">+0.129</td><td align="center" rowspan="1" colspan="1">.057</td><td align="center" rowspan="1" colspan="1">&#x02212;0.027</td><td align="center" rowspan="1" colspan="1">.703</td></tr><tr><td rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">+0.024</td><td align="center" rowspan="1" colspan="1">.732</td><td align="center" rowspan="1" colspan="1">+0.000</td><td align="center" rowspan="1" colspan="1">.997</td></tr><tr><td rowspan="1" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1">+0.092</td><td align="center" rowspan="1" colspan="1">.230</td><td align="center" rowspan="1" colspan="1">&#x02212;0.154</td><td align="center" rowspan="1" colspan="1">.878</td></tr><tr><td rowspan="1" colspan="1">LDL-C</td><td align="center" rowspan="1" colspan="1">&#x02212;0.013</td><td align="center" rowspan="1" colspan="1">.899</td><td align="center" rowspan="1" colspan="1">+0.064</td><td align="center" rowspan="1" colspan="1">.524</td></tr><tr><td rowspan="1" colspan="1">Triglycerides</td><td align="center" rowspan="1" colspan="1">+0.106</td><td align="center" rowspan="1" colspan="1">.410</td><td align="center" rowspan="1" colspan="1">+0.119</td><td align="center" rowspan="1" colspan="1">.246</td></tr><tr><td rowspan="1" colspan="1">HDL-C</td><td align="center" rowspan="1" colspan="1">+0.082</td><td align="center" rowspan="1" colspan="1">.620</td><td align="center" rowspan="1" colspan="1">+0.204</td><td align="center" rowspan="1" colspan="1">.173</td></tr><tr><td rowspan="1" colspan="1">ApoA-I</td><td align="center" rowspan="1" colspan="1">+0.008</td><td align="center" rowspan="1" colspan="1">.961</td><td align="center" rowspan="1" colspan="1">+0.260</td><td align="center" rowspan="1" colspan="1">.062</td></tr><tr><td rowspan="1" colspan="1">ApoA-II</td><td align="center" rowspan="1" colspan="1">&#x02212;0.086</td><td align="center" rowspan="1" colspan="1">.384</td><td align="center" rowspan="1" colspan="1">+0.062</td><td align="center" rowspan="1" colspan="1">.473</td></tr><tr><td rowspan="1" colspan="1">ApoB</td><td align="center" rowspan="1" colspan="1">+0.057</td><td align="center" rowspan="1" colspan="1">.676</td><td align="center" rowspan="1" colspan="1">&#x02212;0.031</td><td align="center" rowspan="1" colspan="1">.789</td></tr><tr><td rowspan="1" colspan="1">Estrogen use</td><td align="center" rowspan="1" colspan="1">+0.166</td><td align="center" rowspan="1" colspan="1">.026</td><td align="center" rowspan="1" colspan="1">+0.161</td><td align="center" rowspan="1" colspan="1">.036</td></tr><tr><td rowspan="1" colspan="1">ApoE grouping</td><td align="center" rowspan="1" colspan="1">&#x02212;0.150</td><td align="center" rowspan="1" colspan="1">.023</td><td align="center" rowspan="1" colspan="1">&#x02212;0.178</td><td align="center" rowspan="1" colspan="1">.011</td></tr></tbody></table><table-wrap-foot><fn><p>The adjusted multiple <italic>R</italic><sup>2</sup> is 0.202 (<italic>P</italic> &#x0003c; .001) for low-HDL subjects and 0.326 (<italic>P</italic> &#x0003c; .001) for normolipidemic subjects when all variables are included. The dependent variable in low-HDL family members is the family number adjusted residual of log CRP, and in normolipidemic subjects, the dependent variable is log CRP. Variables with skewed distribution were log-transformed before entering into the model.</p></fn></table-wrap-foot></table-wrap></sec></back></article> 